1. Introduction {#sec1-ijerph-14-00329}
===============

Chlorine dioxide, a strong oxidant, can inhibit or destroy microbes \[[@B1-ijerph-14-00329],[@B2-ijerph-14-00329],[@B3-ijerph-14-00329],[@B4-ijerph-14-00329],[@B5-ijerph-14-00329]\]. Studies have investigated the application of chlorine dioxide in numerous fields such as water or wastewater treatment, environment and food disinfection, and medicine \[[@B6-ijerph-14-00329],[@B7-ijerph-14-00329],[@B8-ijerph-14-00329],[@B9-ijerph-14-00329],[@B10-ijerph-14-00329],[@B11-ijerph-14-00329],[@B12-ijerph-14-00329],[@B13-ijerph-14-00329]\]. Typically, chlorine dioxide is produced using either an acid-based or an electrolytic method \[[@B7-ijerph-14-00329],[@B8-ijerph-14-00329],[@B10-ijerph-14-00329],[@B12-ijerph-14-00329]\]. In the acid-based method, chlorine dioxide is produced by mixing starting materials, such as sodium chlorite and hydrochloric acid, sodium chlorite and ferric trichloride, or sodium chlorite and chlorine gas. In the electrolytic method, the reactants are aqueous sodium chloride or saturated saline and sodium hypochlorite.

According to the disinfectants and disinfection byproducts rule (DBPR) of the United States Environmental Protection Agency Microbial and Disinfection Byproduct Rules Simultaneous Compliance Guidance Manual \[[@B14-ijerph-14-00329]\], the maximum residual disinfectant level goals (MRDLG) and maximum residual disinfectant levels (MRDL) of chlorine dioxide are 0.8 mg/L \[[@B14-ijerph-14-00329]\]. The permissible exposure limits (PELs) for chlorine dioxide defined by the Occupational Safety and Health Administration are as follows: (a) General industry: 0.1 ppm and 0.3 mg/m^3^; (b) Construction industry: 0.1 ppm and 0.3 mg/m^3^ time weighted average (TWA); (c) American Conference of Governmental Industrial Hygienists threshold limit value: 0.1 ppm and 0.28 mg/m^3^ TWA; 0.3 ppm and 0.83 mg/m^3^ short term exposure limit (STEL); (d) National Institute for Occupational Safety and Health recommended exposure limit: 0.1 ppm TWA; 0.3 ppm STEL.

The application of chlorine dioxide products or their contact with food or the human body is a serious issue if the products contain high levels of impurities. Impurities are mainly caused by impure reactants such as 10% H~2~SO~4~ and 15% NaClO~2~ or reaction byproducts such as Cl~2~ and chloroxy anion. For example, 10% H~2~SO~4~ and 15% NaClO~2~ contain 90% and 85% unknown impurities, respectively. The chlorine dioxide product obtained from a mixture of 10% H~2~SO~4~ and 15% NaClO~2~ is highly impure. The Cl~2~ product can react with organic matter to form trihalomethane, which is a carcinogen. Chloroxy anions, such as ClO~2~^−^ or ClO~3~^−^, can be harmful to human health \[[@B15-ijerph-14-00329]\].

The domestic and industrial use of chlorine dioxide should be assessed according to product purity, for which the preparation method is an essential step. Low purity starting materials (e.g., 5% HCl and 10% NaClO~2~) have a high impurity content. If the product of these reactions is not further purified, then the chlorine dioxide products produced, which also contain high levels of impurities, are useful only for wastewater treatment and are unsuitable for contact with humans or food because of the harmful impurities. Therefore, a higher percentage of chlorine dioxide gas molecules must be obtained through further chlorine dioxide gas molecule purification.

To increase the safety of chlorine dioxide solution, eliminating or reducing the impurities and increasing the gas chlorine dioxide concentration in a solution is a reasonable approach. Herein, a clean and concentrated process for chlorine dioxide gas production was designed and implemented. We produced a chlorine dioxide solution (UC-1) containing 2000 ppm chlorine dioxide gas in water through the electrolytic method. The solution was further purified with a film membrane, and subsequently dissolved in reverse osmosis (RO) water. UC-1 was investigated to determine its efficacy, and safety issues such as the antimicrobial activity, in vitro cytotoxicity, in vivo rabbit ocular irritation, in vivo inhalation toxicity, and in vivo subchronic oral toxicity were assessed.

2. Materials and Methods {#sec2-ijerph-14-00329}
========================

2.1. Electrolytic Method for Gas Chlorine Dioxide Production {#sec2dot1-ijerph-14-00329}
------------------------------------------------------------

The UC-1 solution is produced in an apparatus, the technical details of which will be published later in the form of a patent application (PCT applied PCT/CN2016/080198; PCT applied PCT/CN2016/080199; PCT applied PCT/CN2015/099515; DE202016103175) by an electrochemical method. Briefly, sodium chloride solution was made from 99% (food grade) sodium chloride and RO water and pumped into the electrobath equipment. The electrolysis was operated by 6--12 V and 40--80 A current. After electrolysis, the ClO~2~ gas was mixed with water using a water-ClO~2~ mixer which was designed based on the Venturi effect. Mixing of water with ClO~2~ gas was continued by the cycle till the concentration of ClO~2~ in water was over 2000 ppm ([Figure 1](#ijerph-14-00329-f001){ref-type="fig"}) and pH value was 2.2. The chlorine dioxide solution produced by this process is named as UC-1.

The chemical composition of the UC1 solution was determined according to a standard method \[[@B16-ijerph-14-00329]\]. The following data were obtained: ClO~2~: 2120 ppm, free chlorine (Cl~2~): 882 ppm, and total chlorine (Cl~2~ + HOCl + OCl^−^): 900 ppm. The total chlorine concentration is somewhat higher than in the case of other ClO~2~ generators because the electrolyte applied by us does not contain any NaClO~2~. The UC-1 solution was produced by using only 25% NaCl solution, with no other additive, which is an obvious advantage. At the same time, despite the higher total chlorine content (which is present in the diluted UC-1 solutions mostly as HOCl), no detectable adverse effects were observed on the test animals or animal tissues.

2.2. Antimicrobial Efficacy Test {#sec2dot2-ijerph-14-00329}
--------------------------------

The test was performed following U.S. Pharmacopeia 34 NF29 Microbiological Tests/\<51\> \[[@B17-ijerph-14-00329]\]. Antimicrobial Effectiveness Testing. The test organisms were as follows: *Escherichia coli* (BCRC 11634/ATCC 8739), *Staphylococcus aureus* (BCRC 10451/ATCC 6538P), *Pseudomonas aeruginosa* (BCRC 11633/ATCC 9027), *S. aureus subsp. aureus* (BCRC 15211/ATCC 33591), *Bacillus subtilis subspecies*. (BCRC 10447/ATCC 6633), *Listeria monocytogenes* (BCRC 14848/ATCC 19114), *Acinetobacter baumannii* (BCRC 10591/ATCC 19606), *Salmonella enterica subspecies*. (BCRC 12947/ATCC 13311), *Klebsiella pneumoniae* (BCRC 16082/ATCC 4352), *Penicillium funiculosum* (BCRC 30438/ATCC 11797), and *Candida albicans* (BCRC 21538/ATCC10231).

2.3. Antiviral Assay {#sec2dot3-ijerph-14-00329}
--------------------

Viruses were amplified in MDCK/RD cells. MDCK/RD cells were cultured in 10% fetal bovine serum Dulbecco's modified Eagle's medium (FBS DMEM). When the cells reached 90% confluence, they were washed with phosphate-buffered saline (PBS) and infected at a multiplicity of infection of 0.01. Following the infection, 0% FBS DMEM was added, and the cells were incubated at 35 °C in a 5% CO~2~ incubator for 48 h.

A 1-mL cell suspension (6 × 10^5^ cells) was loaded into each well of a 6-well plate, which was incubated at 37 °C for 18--24 h. PBS was used to dilute UC-1 to final concentrations of 0, 25, 50, 100, and 200 ppm in wells reacted with cells and viruses for 2 min at 37 °C. Following the reaction, the total reaction mixture was diluted to 10^−8^. Subsequently, the 10^−8^ dilution mixture was incubated at 37 °C for 48--64 h. The cells were fixed with 10% formalin for 1 h and stained with 0.1% crystal violet for 5 min. The virus-formed plaque number was counted and compared between the test and control groups. The antiviral activity is shown as the percentage of virus control = plaques in the test group/plaques in the control group × 100. The virus control is defined as infected virus with cells without the testing agent and is considered as 100%.

2.4. In Vitro Cytotoxicity Test (MTT Assay) {#sec2dot4-ijerph-14-00329}
-------------------------------------------

Mouse lung fibroblast L929 cells were cultured in complete Eagle minimum essential medium (MEM) and incubated at 37 °C ± 1 °C in 5% ± 1% CO~2~. Furthermore, 100 μL of L929 cell suspension (1 × 10^5^ cells/mL) was transferred into each well of a 96-well cell culture plate. The cells were subsequently incubated at 37 °C ± 1 °C for 24 h ± 2 h. The culture medium was replaced with 100 μL of the test solution or blank, positive, or negative control. The test solutions contained 0 (control), 200, 400, 600, and 800 ppm UC-1 in MEM. The blank control medium contained 10% horse serum. The cells were incubated for another 24 h. The cells were treated with the solutions in triplicate. After the MTT solution was added to each well, the plate was incubated for 2 h ± 10 min at 37 °C ± 1 °C. The MTT solution was replaced with 100 μL of dimethyl sulfoxide and subsequently subjected to a microplate reader equipped with a 570-nm filter for colorimetric measurement (reference, 650 nm). The triplicate results of the MTT assay are presented as mean ± standard deviation (SD). Cell viability (%) = optical density of the test group/optical density of the control group × 100.

2.5. White Rabbit Ocular Irritation Test {#sec2dot5-ijerph-14-00329}
----------------------------------------

Six 2--3-kg female New Zealand white rabbits were purchased from the Taiwan Livestock Research Institute (Xinhua, Tainan, Taiwan); the rabbits were quarantined and acclimatized before treatment. The animals were fed ad libitum and maintained at 20--26 °C under 30%--70% humidity. Furthermore, 0.1 mL of 50 ppm UC-1 (test solution) was administered to the left eye of the rabbits, and 0.1 mL of 0.9% normal saline (control solution) was administered to the right eye. Subsequently, the eyelids were held together for 1 s for instillation. Each treatment was repeated three times. Ocular irritations were observed for at the 1st, 24th, 48th, and 72nd hour using an ophthalmoscope (Welch Allyn, Skaneateles Falls, NY, USA). Extended observation was necessary in case of persistent lesions to determine the progression or reversal of the lesions. Ocular irritation scores were based on the system for grading ocular lesions (ISO 10993-10). When more than one animal in the test group showed a positive result at any stage of the observations, the test component was considered an eye irritant and further testing was not required or performed. When only one of the test groups showed a mild or moderate reaction that was equivocal, the procedure was conducted on three additional animals. When more than half of the eyes showed a positive result at any stage of the observation, the test component was considered an eye irritant. A severe reaction in only one animal was considered sufficient to label the test component as an eye irritant.

2.6. Inhalation Toxicity Test {#sec2dot6-ijerph-14-00329}
-----------------------------

Fifteen 4-week-old BALB/c male mice were purchased from the National Laboratory Animal Center (Taipei, Taiwan); they were quarantined and acclimatized before treatment in an animal room at China Medical University, Taiwan. The animals were fed ad libitum and maintained at 20--25 °C and 65%--80% humidity. Five mice were housed in one cage and fed with 0 (PBS) and 10 or 20 ppm UC-1 (test solution), which was administered as mist by using a humidifier in an airtight box for 24 h. The clinical symptoms and body weight of the animals were observed; they were subsequently sacrificed to examine their lung sections and organ weight. The experimental animals were observed, and their clinical symptoms were recorded as abnormality (%), defined as the animals behaving abnormally compared with normal animals, and mortality (%), defined as animal death.

### 2.6.1. Evaluation of the Organ Weight {#sec2dot6dot1-ijerph-14-00329}

During the experiment, the animals were immediately dissected on death, and a record was made. All surviving animals were sacrificed and autopsied to observe their appearance and all organs in the mouth, chest, and cranial and abdominal cavities. Subsequently, the organs, including the liver, adrenal glands, kidneys, and gonads, were removed, weighed, and recorded.

### 2.6.2. Hematoxylin and Eosin Staining of Mouse Lung Sections {#sec2dot6dot2-ijerph-14-00329}

Tissue sections frozen in the optimal cutting temperature compound were fixed in acetone and chloroform; the sections were immersed in filtered Harris hematoxylin (Leica Biosystems Richmond, Inc., Richmond, IL, USA) for 1 min. The slides were rewashed with Tris-buffered saline and Tween 20 (Biokit Biotechnology Inc., Miaoli, Taiwan), and the sections were counterstained with eosin (Leica Biosystems Richmond, Inc., Richmond, IL, USA) for 1--2 min. The sections were dehydrated in ascending alcohol solutions and cleared with xylene. The prepared slides were examined through light microscopy.

2.7. Subchronic Oral Toxicity Test {#sec2dot7-ijerph-14-00329}
----------------------------------

Twenty-five 4-week-old BALB/c male mice were purchased from the National Laboratory Animal Center; they were quarantined and acclimatized before treatment in an animal room at China Medical University. The animals were fed ad libitum and maintained at 20--25 °C under 65%--80% humidity. Five mice were housed in one cage and fed 0 (PBS; control), 5, 10, 20, and 40 ppm UC-1 (test solutions) continuously for 90 days. PBS or test solutions fed as drinking water were freshly prepared daily before treatments.

### 2.7.1. Evaluation of the Clinical Symptoms {#sec2dot7dot1-ijerph-14-00329}

The experimental animals were observed, and their clinical symptoms were recorded as abnormality (%), defined as the animals behaving abnormally compared with normal animals, and mortality (%), defined as animal death.

### 2.7.2. Body Weight {#sec2dot7dot2-ijerph-14-00329}

The body weight of the experimental animals was recorded at treatment initiation and once per week during the experimental period using an electronic balance (AND, FX-2000i, Tokyo, Japan).

### 2.7.3. Necropsy, Gross Examination, and Organ Weighing {#sec2dot7dot3-ijerph-14-00329}

During the experiment, the animals were dissected immediately on death, and a record was made. All surviving animals were sacrificed and autopsied to observe their appearance, and all organs in the mouth, chest, and cranial and abdominal cavities were analyzed. Subsequently, the organs, including the liver, adrenal glands, kidneys, and gonads, were removed, weighed, and recorded.

2.8. Statistical Analysis {#sec2dot8-ijerph-14-00329}
-------------------------

The results were analyzed using SPSS Version 20.0 (IBM Corp., Armonk, NY, USA) with one-way analysis of variance, *F*-test, and Duncan's new multiple range test for comparing more than two mean values; results with *p* \< 0.05 indicated significant differences. The results represent at least 3 independent experiments and are shown as the mean ± SD.

2.9. Ethical Statement {#sec2dot9-ijerph-14-00329}
----------------------

This research was approved by the China Medical University Laboratory Animal Service Center. Program Number: 10442699 (for the white rabbit ocular irritation test) and 10442686 (for the inhalation toxicity and subchronic oral toxicity tests).

3. Results {#sec3-ijerph-14-00329}
==========

In this study, a UC-1 containing 2000 ppm chlorine dioxide in water was produced through the electrolytic method with food-grade salt (99% NaCl) and RO water as the starting reactants. Subsequently, the chlorine dioxide was purified through a film and dissolved in RO water. Because a chlorine dioxide solution can be directly applied to food or human hygiene or preventative health measures, its safety and efficacy were investigated.

3.1. Antimicrobial Efficacy Test {#sec3dot1-ijerph-14-00329}
--------------------------------

The in vitro antimicrobial activity of UC-1 was examined. The in vitro antimicrobial activity was more than 98.2% reduction for bacteria and fungi ([Table 1](#ijerph-14-00329-t001){ref-type="table"}); excellent antimicrobial activity was observed at low concentrations of 5 and 20 ppm UC-1 for bacteria and fungi, respectively.

3.2. Antiviral Assay {#sec3dot2-ijerph-14-00329}
--------------------

The antiviral activity of 0, 25, 50, 100, and 200 ppm UC-1 after 2 min of reaction is shown in [Figure 2](#ijerph-14-00329-f002){ref-type="fig"}. For H1N1 and influenza virus B/TW/71718/04, 200 ppm UC-1 had the most significant effect in inhibiting viral plaque formation. The half maximal inhibitory concentration (IC~50~) of H1N1 was 84.65 ± 0.64 ppm and that of influenza virus B/TW/71718/04 was 95.91 ± 11.61 ppm. For EV71, 50 ppm UC-1 showed significant inhibition activity, with an IC~50~ of 46.39 ± 1.97 ppm at 2 min. The results showing statistical significance (*p* \< 0.05) are presented. Bars are plotted as means ± SD.

3.3. In Vitro Cytotoxicity Test (MTT Assay) {#sec3dot3-ijerph-14-00329}
-------------------------------------------

The cytotoxic effect of 0, 200, 400, 600, and 800 ppm UC-1 against L929 lung fibroblast cells was analyzed. The cell viability was 74.0%--100.0% at UC-1 concentrations below 600 ppm. L929 cell viability was reduced to 40.3% at 800 ppm UC-1 ([Figure 3](#ijerph-14-00329-f003){ref-type="fig"}).

3.4. Ocular Irritation Test {#sec3dot4-ijerph-14-00329}
---------------------------

The cornea, iris, and conjunctivae were evaluated in a rabbit ocular irritation test. The 50 ppm UC-1 solution induced neither significant clinical signs nor ocular gross changes in the rabbits at each time point ([Table 2](#ijerph-14-00329-t002){ref-type="table"}). Therefore, single ocular applications with 0.1 mL of 50 ppm UC-1 did not cause ocular irritation in rabbits.

3.5. Inhalation Toxicity Test {#sec3dot5-ijerph-14-00329}
-----------------------------

In an inhalation toxicity test, we used 0, 10, and 20 ppm UC-1, which was administered as mist by using a humidifier in an airtight box containing five mice. The test showed no abnormality and no mortality for the control and test components within 24 h ([Table 3](#ijerph-14-00329-t003){ref-type="table"}). The weights of the heart, liver, spleen, and kidney of the test group did not differ significantly from those in the control group ([Table 4](#ijerph-14-00329-t004){ref-type="table"}). Hematoxylin and eosin staining of the mice lung sections ([Figure 4](#ijerph-14-00329-f004){ref-type="fig"}) showed that 10 and 20 ppm UC-1 did not induce significant clinical signs of changes in the mouse lung cells at 24 h. Therefore, inhalation of 10 and 20 ppm UC-1 did not cause irritation in the mice.

3.6. Subchronic Oral Toxicity Test {#sec3dot6-ijerph-14-00329}
----------------------------------

In the subchronic oral toxicity test, 0, 5, 10, 20, and 40 ppm UC-1 was prepared to feed the mice. Clinical observations of the mice showed no abnormality and no mortality after 90 days for the control and test groups ([Table 5](#ijerph-14-00329-t005){ref-type="table"}). The mouse weight was not influenced ([Figure 5](#ijerph-14-00329-f005){ref-type="fig"}). Moreover, necropsy and gross examination did not show any pathological symptoms ([Figure 6](#ijerph-14-00329-f006){ref-type="fig"}). The weights of the heart, liver, spleen, and kidney of the test groups did not differ significantly compared with those in the control group ([Table 6](#ijerph-14-00329-t006){ref-type="table"}). Therefore, administration of up to 40 ppm UC-1 to mice for 90 days is nontoxic.

4. Discussion {#sec4-ijerph-14-00329}
=============

UC-1 with gas chlorine dioxide and fewer impurities was prepared using a patented green process design, and the efficacy and safety of UC-1 were evaluated. Many studies have reported the potent oxidant and antimicrobial activity of chlorine dioxide in vitro. Recent reports have addressed concerns related to microbial decontamination of food by chlorine dioxide \[[@B6-ijerph-14-00329],[@B9-ijerph-14-00329],[@B18-ijerph-14-00329],[@B19-ijerph-14-00329],[@B20-ijerph-14-00329],[@B21-ijerph-14-00329]\]. In these studies, chlorine dioxide was produced using various methods (e.g., 2% NaClO~2~ with H~3~PO~4~, 4% Cl~2~ with 80% NaClO~2,~ and by using an electrogenerator); the antimicrobial activity was more than 2% for 5--75 mg/L ClO~2~ within 5--30 min. Here, the antimicrobial activity was more than 98.2% reduction at UC-1 concentrations of 5 and 20 ppm for bacteria and fungi, respectively. In the MTT test, the viability of L929 cells was 93.7% at 200 ppm UC-1 that a concentration is over routine use.

No significant symptoms were observed with 50 ppm UC-1 in the ocular irritation test. No abnormality or mortality was observed in clinical symptoms, lungs, and other organs at 10 ppm or 20 ppm UC-1 in the inhalation toxicity test. Paulet and Desbrousses \[[@B22-ijerph-14-00329]\] administered 2.5, 5, and 10 ppm chlorine dioxide to rats and rabbits in 1970; they reported that 2.5 ppm chlorine dioxide had the lowest-observed-adverse-effect level (LOAEL), causing thoracic effects in rats at 7 h/day for 30 days and pulmonary effects in rabbits at 4 h/day for 45 days. Paulet and Desbrousses \[[@B23-ijerph-14-00329]\] increased the test concentration to 5, 10, and 15 ppm chlorine dioxide and reduced the dose time to 15 min per dose, 2--4 times per day, for 4 weeks in rats. The results showed a no-observed-averse-effect level (NOAEL) of 5 ppm and an LOAEL of 10 ppm for lung damage.

The mice were fed drinking water containing up to 40 ppm UC-1 for 90 days; the concentration showed no toxicity in the sub-chronic orally toxicity test. Daniel et al. \[[@B24-ijerph-14-00329]\] reported the oral exposed toxicity of chlorine dioxide in drinking water administered to Sprague--Dawley rats for 90 days; they used different concentrations of chlorine dioxide (0, 25, 50, 100, and 200 mg/L corresponding to doses of 0, 2, 5, 8, and 15 mg/kg·day). The spleen and liver weight decreased significantly at 25 and 50 mg/L, respectively. They showed nasal lesions caused by 25 mg/L chlorine dioxide vapors in drinking water. In that study, the LOAEL was 25 mg/L. Bercz et al. \[[@B25-ijerph-14-00329]\] conducted a similar test in African green monkeys (*Cercopithecus aethiops*) by using 0, 30, 100, and 200 mg/L chlorine dioxide for 4--6 weeks. Furthermore, 200 mg/L chlorine dioxide caused erythema and ulceration of the oral mucosa after 1 week, and 100 mg/L chlorine dioxide reduced the serum thyroxine (T4) levels after 6 weeks; in that study, the NOAEL was 30 mg/L and LOAEL was 100 mg/L for the oral exposure of the monkeys.

5. Conclusions {#sec5-ijerph-14-00329}
==============

UC-1 was produced through a green process with clean starting materials and procedures. UC-1 solution demonstrated satisfactory antibacterial, antifungal, and antiviral activity. Low toxicity was demonstrated through an in vitro cytoxicity test (high IC~50~ 765 ± 18 ppm), 50 ppm ClO~2~ did not cause eye irradiation in an ocular irritation test, mice did not exhibit abnormality and mortality in a 20 ppm ClO~2~ inhalation toxicity test, and concentrations of UC-1 up to 40 ppm were nontoxic to mice for 90 days in subchronic oral toxicity test. Therefore, a higher safety profile for UC-1 than those yielded in previous studies was demonstrated.
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ijerph-14-00329-t001_Table 1

###### 

Antimicrobial efficacy of UC-1.

  Organisms                                        Original Inoculum (CFU/mL)   Counts of UC-1 at Contact Time ^a^ (CFU/mL)   Percent Reductions (R) ^b^
  ------------------------------------------------ ---------------------------- --------------------------------------------- ----------------------------
  *Escherichia coli ^c,^*\*                        2.55 × 10^5^                 \<1                                           \>99.9
  *Staphylococcus aureus ^c^*^,^\*                 3.15 × 10^5^                 \<1                                           \>99.9
  *Pseudomonas aeruginosa ^c^*^,^\*                2.55 × 10^5^                 \<1                                           \>99.9
  *Staphylococcus aureus subsp. Aureus ^c^*^,^\*   2.60 × 10^5^                 \<1                                           \>99.9
  *Bacillus subtilis subspecies ^c^*^,^\*          3.75 × 10^5^                 1.35 × 10^3^                                  99.6
  *Listeria monocytogenes ^c^*^,^\*                8.20 × 10^5^                 \<1                                           \>99.9
  *Acinetobacter baumannii ^c^*^,^\*               5.40 × 10^5^                 \<1                                           \>99.9
  *Salmonella enterica subspecies ^c^*^,^\*        4.80 × 10^5^                 \<1                                           \>99.9
  *Klebsiella pneumoniae ^c^*^,^\*                 9.30 × 10^5^                 \<1                                           \>99.9
  *Penicillium funiculosum* ^,*c*Δ^                3.70 × 10^5^                 6.70 × 10^3^                                  98.2
  *Candida albicans ^c^*^,Δ^                       3.20 × 10^5^                 \<1                                           \>99.9

^a^ The contact time was 10 min. ^b^ Percent reductions of \<1% represent no significant bacteriostasis or fungistasis. ^c^ UC-1 concentrations were 5 and 20 ppm for bacteria and fungi, respectively. \* presented as bacteria; ^Δ^ presented as fungi. CFU: colony-forming unit.

ijerph-14-00329-t002_Table 2

###### 

Grades in the clinical observation of individual rabbits for the ocular irritation test.

  Applied Regions   Test Component          Animal No.     Items for Grading   Clinical Observation (Time point/h)           
  ----------------- ----------------------- -------------- ------------------- ------------------------------------- --- --- ---
  Left Eye          Test (50 ppm UC-1)      RB-160114-01   Cornea              0                                     0   0   0
  Iris              0                       0              0                   0                                             
  Conjunctivae      0                       1              0                   0                                             
  RB-160114-03      Cornea                  0              0                   0                                     0       
  Iris              0                       0              0                   0                                             
  Conjunctivae      0                       0              0                   0                                             
  RB-160114-06      Cornea                  0              0                   0                                     0       
  Iris              0                       0              0                   0                                             
  Conjunctivae      0                       0              0                   0                                             
  Right Eye         Control (0.9% Saline)   RB-160114-01   Cornea              0                                     0   0   0
  Iris              0                       0              0                   0                                             
  Conjunctivae      0                       0              0                   0                                             
  RB-160114-03      Cornea                  0              0                   0                                     0       
  Iris              0                       0              0                   0                                             
  Conjunctivae      0                       0              0                   0                                             
  RB-160114-06      Cornea                  0              0                   0                                     0       
  Iris              0                       0              0                   0                                             
  Conjunctivae      0                       0              0                   0                                             

ijerph-14-00329-t003_Table 3

###### 

Evaluation of clinical symptoms in the inhalation toxicity test.

  Test Component   Animal No.   Abnormality Rate (%)   Mortality (%)
  ---------------- ------------ ---------------------- ---------------
  Control: PBS     5            0                      0
  10 ppm UC-1      5            0                      0
  20 ppm UC-1      5            0                      0

PBS: phosphate-buffered saline.

ijerph-14-00329-t004_Table 4

###### 

Evaluation of organ weight for the inhalation toxicity test.

  Test Component   Heart (g)   Liver (g)   Spleen (g)   Kidney (g)
  ---------------- ----------- ----------- ------------ ------------
  Control: PBS     0.3 ± 0.1   0.7 ± 0.2   0.5 ± 0.1    0.6 ± 0.1
  10 ppm UC-1      0.4 ± 0.1   0.7 ± 0.2   0.5 ± 0.2    0.6 ± 0.2
  20 ppm UC-1      0.3 ± 0.2   0.8 ± 0.1   0.6 ± 0.1    0.6 ± 0.2

Statistical analyses of the presented data were performed at the 95% significance level (*p* \< 0.05).

ijerph-14-00329-t005_Table 5

###### 

Evaluation of clinical symptoms in the subchronic oral toxicity test.

  Test Component   Animal No.   Abnormality Rate (%)   Mortality (%)
  ---------------- ------------ ---------------------- ---------------
  Control: PBS     5            0                      0
  5 ppm UC-1       5            0                      0
  10 ppm UC-1      5            0                      0
  20 ppm UC-1      5            0                      0
  40 ppm UC-1      5            0                      0

ijerph-14-00329-t006_Table 6

###### 

Evaluation of organ weight in the subchronic oral toxicity test.

  Test Component   Heart (g)   Liver (g)   Spleen (g)   Kidney (g)
  ---------------- ----------- ----------- ------------ ------------
  Control: PBS     0.4 ± 0.1   0.8 ± 0.2   0.5 ± 0.1    0.7 ± 0.1
  5 ppm UC-1       0.5 ± 0.2   0.8 ± 0.3   0.6 ± 0.1    0.6 ± 0.2
  10 ppm UC-1      0.4 ± 0.2   0.9 ± 0.1   0.5 ± 0.3    0.7 ± 0.2
  20 ppm UC-1      0.4 ± 0.1   0.8 ± 0.2   0.5 ± 0.1    0.7 ± 0.1
  40 ppm UC-1      0.5 ± 0.1   0.8 ± 0.3   0.5 ± 0.1    0.6 ± 0.1

Statistical analyses of the presented data were performed at the 95% significance level (*p* \< 0.05).
